Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.
Similar Posts
Mesalazine and idiopathic intracranial hypertension
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products.
MHRA seizes illegal medicines worth almost £45m in 2025 – disrupting major criminal networks
Nearly 20 million doses of potentially dangerous medicines prevented from reaching the public
Class 4 Medicines Defect Notification: Flamingo Pharma UK Ltd, Amitriptyline Hydrochloride 10mg, 25mg, 50mg Tablets, EL(25)A/52
Flamingo Pharma UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.
Corporate report: MHRA: policy for handling corporate conflicts of interest
Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.
Guidance: Digital mental health technology: qualification and classification
Helping manufacturers define the characteristics of their devices and determine the appropriate regulatory qualification and classification.
Field Safety Notices: 23-27 February 2026
List of Field Safety Notices from 23-27 February 2026.